BACKGROUND: The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with¯utamide and metformin than by either of these drugs in monotherapy. In this follow-up study, we assess whether the endocrine-metabolic bene®ts of combined utamide-metformin treatment are maintained in the presence of a low-dose oral contraceptive (OC). METHODS: To a population of non-obese, young PCOS women already receiving¯utamide-metformin (125 mg/day and 1275 mg/day), a low-dose OC (ethinyl estradiol 20 mg + gestodene 75 mg) was administered to reduce the risk of pregnancy. A total of 12 women elected to receive the OC and this subgroup (OC+) was matched to a subgroup continuing on¯utamide-metformin alone (OC±), for a total study population of 24 women (mean age T T SEM 18.7 T T 0.3 years; body mass index, 21.8 T T 0.5 kg/m 2 ). Endocrine-metabolic indices were assessed before any treatment (0 months), on¯utamide-metformin (12 months), and again after a further 6 months with or without additional OC (18 months). RESULTS: In OC± and OC+ women, the bene®cial effects of¯utamide-metformin on hyperandrogenaemia, hyperinsulinaemia and dyslipidaemia were maintained. In OC+ women, there was an additional increase in sex hormone-binding globulin (SHBG), and thus a further drop in the free androgen index. CONCLUSION: When a low-dose OC is administered with a low-dose¯utamide-metformin combination in women with PCOS, the bene®-cial effects are maintained on hyperinsulinaemia-dyslipidaemia, which are key determinants of long-term complications. Hence, in daily practice, such a low-dose quatuor may become a therapeutic option of ®rst choice for young women with PCOS.
Introduction
Monotherapies with insulin-sensitizing and anti-androgen agents have been used in the treatment of adolescents and young women with polycystic ovary syndrome (PCOS) (i.e., hyperinsulinism, hyperandrogenism, dyslipidaemia and anovulation) (Nestler and Jakubowicz, 1997; de Leo et al., 1998; Nestler et al., 1998; Iba Ân Äez et al., 2000a Iba Ân Äez et al., ,b, 2001 Moghetti et al., 2000; Azziz et al., 2001) . These monotherapies are partially effective treatments that act through different pathways and, accordingly, have a different spectrum of endocrine-metabolic actions (Simard et al., 1986; Stumvoll and Ha Èring, 2001) .
The endocrine-metabolic status of 31 non-obese, young women with PCOS was recently found to be normalized more effectively by combined treatment with¯utamide (250 mg/day) and metformin (1275 mg/day) than by either of these drugs in monotherapy, over 9 months;¯utamide-metformin proved particularly effective in correcting dyslipidaemia and hyperandrogenaemia (Iba Ân Äez et al., 2002 ).
An epi-phenomenon of¯utamide-metformin therapy was a striking increment in the ovulation rate, thus pointing to the possible need for concomitant contraception (since¯utamide is contra-indicated in pregnancy) and raising the question whether the bene®ts of the combined¯utamide-metformin treatment would be maintained, if an oral contraceptive (OC) were added (Iba Ân Äez et al., 2002) .
To answer this question, we report here on the course of the original study cohort (Iba Ân Äez et al., 2002) during the 9 months following a period of 9 months on¯utamide and/or metformin treatment, for a total follow-up of 18 months.
Materials and methods

Study population
The original cohort consisted of 31 non-obese, young women (mean age T SEM: 18.7 T 0.3 years; range, 18±22) who were 5±10 years beyond menarche and who were using a non-hormonal contraceptive method, if any (Iba Ân Äez et al., 2002). All women had: (i) hyperinsulinaemia on standard 2 h oral glucose tolerance testing (oGTT), de®ned as peak serum insulin concentration >150 mU/ml (Vidal-Puig and Moller, 1997) and/or mean serum insulin (MSI) >84 mU/l (Iba Ân Äez et al., 1997); (ii) ovarian hyperandrogenism, as de®ned by hirsutism (score b8 on Ferriman-Gallwey scale) (Ferriman and Gallwey, 1961) , plus elevated serum androstenedione, total testosterone and/or free androgen index [testosterone Q 100/sex hormone-binding globulin (SHBG)], an index of free testosterone (Iba Ân Äez et al., 1994) ; and 17-hydroxyprogesterone (17-OHP) hyperresponse (>160 ng/dl) to leuprolide acetate, a GnRH agonist (Procrin, Abbott, Madrid, Spain) (Iba Ân Äez et al., 1994) .
None of the women had a body mass index (BMI) >25 kg/m 2 ; thyroid dysfunction; hyperprolactinaemia; abnormal glucose tolerance (The Expert Committee on the Diagnosis and Classi®cation of Diabetes Mellitus, 1997); a family or personal history of diabetes mellitus; late-onset congenital adrenal hyperplasia (New et al., 1983; Sakkal-Alkadour et al., 1996) ; evidence of thromboembolic or hepatic disease, or was receiving a medication known to affect gonadal or adrenal function, or carbohydrate-or lipid-metabolism.
Study design
The study protocol is summarized in Figure 1 . At the start of the study, women were randomized to receive, once daily,¯utamide (Eulexin, Schering-Plough, Spain, 250 mg), metformin (Dianben, AndreuRoche, Spain, 1275 mg) or¯utamide-metformin (250 mg and 1275 mg) for 9 months (Iba Ân Äez et al., 2002) . Between months 9±12, all women received¯utamide-metformin (Flu-Met), but with a lower utamide dose (125 mg/day). Between months 12±18, a monophasic, low-dose estro-progestogen OC (ethinyl estradiol 20 mg + gestodene 75 mg; Meliane, Schering) was also taken to avoid pregnancy risk. A total of 12 young women elected to take an OC (OC+), and this subgroup was then matched to a subgroup of 12 women who continued on Flu-Met alone (OC±); clinical and endocrine-metabolic variables were matched, not only at 0 months, but also at 12 months, by which time a considerable normalization of the endocrinemetabolic state had occurred (Tables I and II) .
Fasting serum glucose and insulin were assessed at 12 and 18 months, together with LH, FSH, estradiol, testosterone, androstenedione, dehydroepiandrosterone-sulphate (DHEAS), SHBG, and lipid pro®le. Blood count and liver and kidney function were also screened as additional safety variables.
Hormonal assays
Serum glucose was measured by the glucose oxidase method. Immunoreactive insulin was assayed by IMx (Abbott Diagnostics, Santa Clara, CA, USA). The mean intra-and inter-assay coef®cients of variation (CVs) were 4.7 and 7.2% respectively. LH, FSH and progesterone were measured by immuno-chemiluminescence (IMMULITE 2000; Diagnostic Products Corp, Los Angeles, CA, USA), with CVs of 3.5 and 5.0% for LH, 4.6 and 6.3% for FSH, and 7.8 and 8.5% for progesterone. Serum testosterone, 17-OHP, androstenedione, estradiol, SHBG and DHEAS levels were assayed as previously described (Iba Ân Äez et al., 2002) . Serum samples were kept frozen at ±20°C until assay.
Statistics and ethics
Results are expressed as mean T SEM. Two-sided t-test was used for statistical comparisons, unless mentioned otherwise; signi®cance level was set at P < 0.01.
The study protocol was approved by the Institutional Review Board of Sant Joan de De Âu, Barcelona University Hospital. Informed consent was obtained from each woman.
Results
Table II displays the clinical characteristics and endocrinemetabolic variables at baseline (0 months), and after 12 and 18 months of study.
Comparisons between results before and after 12 months of Flu-Met therapy allowed us to appreciate the broad and major impact of such combined treatment: marked decreases in hirsutism score and serum androgens, bene®cial changes in the lipid pro®le and a larger fraction of ovulatory women. These alterations occurred without detectable changes in BMI.
Within the OC± subgroup, 12 versus 18 months comparisons indicate that the newly induced equilibrium remains stable over those 6 months with no signi®cant changes in the clinical or endocrine-metabolic parameters. Such novel equilibrium is also maintained in the OC+ subgroup, except for an additional (and expected) increment in SHBG, and thus a further drop in the free androgen index. Each treatment regimen was well tolerated; indices of hepatic and renal function were stable throughout the study.
Discussion
There is a solid pathophysiological basis for considering a lowdose combination of an anti-androgen and an insulin-sensitizer as a therapeutic approach for non-obese women with hyperinsulinemic hyperandrogenism (Iba Ân Äez et al., 2002) . However, since an increment of ovulation rate is part of the remarkable ef®cacy of this combination, the timely addition of contraceptive measures is a major point of attention. The present ®ndings indicate that the main clinical and endocrine-metabolic bene®ts of a low-dose¯utamide-metformin combination are maintained after the addition of a low-dose third-generation estro-progestogen. Another study design would be needed to verify whether, conversely, the addition of¯utamide-metformin to a low-dose OC does indeed offer additional endocrine-metabolic bene®ts, compared with OC alone. It also remains to be studied, in women receiving an OC, to what extent the addition of low-dose¯utamide-metformin is metabolically superior to the addition of metformin alone.
Monotherapy with OCs has long been considered the ®rst therapeutic approach in PCOS women who wish to get pregnant. These drugs increase circulating SHBG and suppress adrenal and ovarian androgen production, and thus reduce the clinical markers of androgen excess (Coenen et al., 1996; Venturoli et al., 1999) ; in addition, their use does not seem to be associated with an increased risk of breast cancer, even when started at a young age (Marchbanks et al., 2002) . However, the effects of OCs on PCOS-associated dyslipidaemia and hyperinsulinism are still controversial (Crook et al., 1993; Pedersen et al., 2000; Cibula et al., 2002) . For example, a combination of ethinyl estradiol and cyproterone-acetate (2 mg/day), one of the most commonly prescribed regimens for PCOS, is effective in reducing hirsutism (Venturoli et al., 1999) , but may facilitate weight gain and decrease both insulin sensitivity and circulating high-density lipoprotein (HDL)-cholesterol (Venturoli et al., 1999; Morin-Papunen et al., 2000; Carmina., 2002) ; in turn, these adverse effects may be reduced by the addition of metformin (Elter et al., 2002) , but the longterm ef®cacy and safety of such a combination remain to be established.
Combined¯utamide-metformin therapy was well-tolerated in both the OC+ and OC± subgroups. The safety and ef®cacy of metformin in PCOS has been addressed in many populations, including in adolescents and pregnant women (Nestler and Jakubowicz, 1997; Nestler et al., 1998; Iba Ân Äez et al., 2000b Iba Ân Äez et al., , 2001 Moghetti et al., 2000; Glueck et al., 2002 , Jakubowicz et al., 2002 . The side-effects of¯utamide are essentially dosedependent (Muderris et al., 1997) ; hepatotoxicity is a potential complication with daily doses >500 mg (Wysowski et al., 1993) , this cut-off dose being 4-fold higher than the¯utamide dose used in the present study.
In conclusion, when a low-dose OC is added to low-dosē utamide-metformin in women with PCOS, then the bene®cial effects are maintained on hyperinsulinaemia and dyslipidaemia, which are the key determinants of the long-term complications of PCOS. Hence, in daily practice, such a lowdose quatuor may become a therapeutic option of ®rst choice for women with PCOS. Table II . Clinical and endocrine-metabolic variables, in fasting condition, at study start (0 months) and on¯utamide-metformin (Flu-Met; 12 months); thereafter (12±18 months), an oral contraceptive (OC) consisting of a low-dose estro-progestagen was either added to¯utamide-metformin ( Table I ; treatment between 9±12 months: Flutamide (125 mg/day) + Metformin (1275 mg/day). c P < 0.01 versus start. d by c 2 e P < 0.01 versus 12 months. f Testosterone (nmol/l) Q 100/SHBG (nmol/l). SHBG = sex hormone-binding globulin; DHEAS = dehydroepiandrosterone-sulphate. Values are mean T SEM. P-values by two-sided t-test.
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